MENU

Press Releases

  1. Apr 03, 2012

    Amorchem

    PRESS RELEASE
    Montreal, Quebec – April 3, 2012– AmorChem is delighted to announce the closing of a deal with Univalor, the Institut de recherches cliniques de Montréal (“IRCM”) and Dr. Nabil Seidah to pursue the discovery of a new drug to control cholesterol levels. This drug will hit a target called PCSK9, which, when blocked, leads to the significant lowering of cholesterol levels in the blood.

     

    Dr. Nabil Seidah is a pioneer in the field of PCSK9 research and has been working for many years to develop a therapeutic application for the target. “AmorChem is honoured to be collaborating with Dr. Seidah, a world-class scientist and leader in PCSK9 research” explains Dr. Elizabeth Douville from AmorChem. “The importance of PCSK9 was certainly highlighted recently by several companies’ announcements at the Annual Meeting of the American College of Cardiology” she added.
    Read more »

  2. Dec 05, 2011

    Amorchem

    PRESS RESLEASE
    Montreal, Quebec – December 5, 2011– AmorChem Financial Inc. has announced two important developments in its activities as a venture capital fund focusing on life sciences projects in Quebec. They are the launch of a new medicinal chemistry contract research company, NuChem Therapeutics Inc., as well as the appointment of Dr. John Clement as its business development partner.

     

    NuChem Therapeutics Inc. has started operations at Montreal’s Biotechnology Research Institute. Dr. Daniel Guay, formerly with Merck Canada and the Institut de Recherche en Immunologie et Cancérologie, has been chosen to lead the company, leading a team of seven scientists who also gained much of their experience at Merck Canada.
    Read more »